lansoprazole has been researched along with Chronic Disease in 33 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Out of 45 patients referred for unexplained chronic persistent cough, 36 had at least one of the GI investigations (endoscopy, 24-h esophageal pH-metry and a 4-week trial of proton pump inhibitor (PPI) therapy) positive and were randomly assigned to receive either 30 mg lansoprazole o." | 9.12 | Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole. ( Baldi, F; Cappiello, R; Cavoli, C; Ghersi, S; Roda, E; Torresan, F, 2006) |
| "Patients diagnosed with idiopathic chronic laryngitis were randomized to receive either lansoprazole 30 mg p." | 9.09 | Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. ( Buchner, A; El-Serag, HB; Gavin, M; Inadomi, JM; Lee, P; McCarthy, DM, 2001) |
| "Only patients with GERD had significantly (P = 0." | 6.75 | Dilated intercellular space in chronic laryngitis and gastro-oesophageal reflux disease: at baseline and post-lansoprazole therapy. ( Garrett, CG; Goutte, M; Hagaman, D; Jerome, WG; Slaughter, JC; Smith, BS; Vaezi, MF; Washington, MK, 2010) |
| "Out of 45 patients referred for unexplained chronic persistent cough, 36 had at least one of the GI investigations (endoscopy, 24-h esophageal pH-metry and a 4-week trial of proton pump inhibitor (PPI) therapy) positive and were randomly assigned to receive either 30 mg lansoprazole o." | 5.12 | Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole. ( Baldi, F; Cappiello, R; Cavoli, C; Ghersi, S; Roda, E; Torresan, F, 2006) |
| "Five patients with gastroesophageal reflux disease (GERD), who also had chronic functional diarrhea and postprandial urgency, unexpectedly noted rapid relief of their diarrhea and urgency when they took lansoprazole for their heartburn." | 5.09 | Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea. ( Dave, B; Rubin, W, 1999) |
| "Patients diagnosed with idiopathic chronic laryngitis were randomized to receive either lansoprazole 30 mg p." | 5.09 | Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. ( Buchner, A; El-Serag, HB; Gavin, M; Inadomi, JM; Lee, P; McCarthy, DM, 2001) |
| "In order to investigate whether chronic duodenal ulcer disease is a consequence of disturbed mucosal turnover and growth factor expression, we studied 16 patients with duodenal ulcers before, during, and after endoscopic healing with lansoprazole or sucralfate." | 5.08 | Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans. ( Marks, IN; O'Keefe, SJ; Ogden, J; Winter, T; Zhang, T, 1998) |
| " pylori-negative subjects with erosive esophagitis (>or= grade 2; n=196), nonerosive reflux disease (n=688), or functional dyspepsia (n=711) who participated in US Takeda-sponsored lansoprazole trials." | 3.76 | Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients. ( Atkinson, S; Haber, MM; Hunt, B; Peura, DA, 2010) |
| "Gastroesophageal reflux (GER) is considered a cause of otitis media with effusion (OME)." | 2.87 | A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion. ( Dewan, K; Lieu, J, 2018) |
| " The incidence of adverse effects of eradication therapy was higher in the group of patients who were not on probiotic (28." | 2.82 | Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study. ( Benedeto-Stojanov, D; Grgov, S; Radovanović-Dinić, B; Tasić, T, 2016) |
| "Only patients with GERD had significantly (P = 0." | 2.75 | Dilated intercellular space in chronic laryngitis and gastro-oesophageal reflux disease: at baseline and post-lansoprazole therapy. ( Garrett, CG; Goutte, M; Hagaman, D; Jerome, WG; Slaughter, JC; Smith, BS; Vaezi, MF; Washington, MK, 2010) |
| "Gastroesophageal reflux is common among patients with postnasal drainage." | 2.75 | Proton pump inhibitor therapy improves symptoms in postnasal drainage. ( Allocco, CT; Clement, LE; Duncavage, JA; Goutte, M; Hagaman, DD; Lanza, DC; McCafferty, BA; Slaughter, JC; Sparkman, C; Tanner, SB; Vaezi, MF; Wasden, CM; Wirth, D, 2010) |
| "Chronic urticaria is a common disease, though only few data on its natural course are available." | 2.69 | Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection. ( Helbling, A; Pichler, WJ; Schnyder, B, 1999) |
| "Gastro-oesophageal reflux disease (GERD) can be effectively treated pharmacologically or surgically." | 2.68 | Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland. ( Isolauri, J; Nevalainen, J; Viljakka, M, 1997) |
| "pylori associated diseases such as gastric cancer is expected." | 2.50 | [Expanded indication of National Health Insurance for H. pylori associated gastritis]. ( Kato, M, 2014) |
| "When lansoprazole was used as monotherapy, the mean Hp eradication was 6% in four studies." | 2.39 | Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies. ( Lamouliatte, H, 1995) |
| " Examination of eradication rates according to CAM dosage revealed an eradication rate of 65." | 1.40 | Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). ( Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A, 2014) |
| "Chronic cough is defined as that which is persisting at least for trhee weeks without an evident cause." | 1.34 | [Otorhinolaringologyc approach of the chronic cough. Clinical case]. ( García de Hombre, AM, 2007) |
| "Gastroesophageal reflux disease (GERD) is commonly associated with asthma; however, frequency in nonatopic children with asthmatic symptoms is unknown." | 1.33 | Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. ( Aydoğdu, S; Kasirga, E; Kirmaz, C; Yilmaz, O; Yüksel, H, 2006) |
| "The cough was eliminated or markedly improved in 38 patients (86%) after 4 weeks and by 8 weeks in the remaining 6 patients." | 1.32 | Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. ( Kallay, MC; Poe, RH, 2003) |
| "Lactoferrin (Lf) is an iron-binding glycoprotein present in milk, lacrimae, saliva, and gastroduodenal secretions." | 1.30 | Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. ( Ikemura, N; Imoto, I; Misaki, M; Nakao, K; Shibata, T; Taguchi, Y; Takaji, S; Yamauchi, K; Yamazaki, N, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (21.21) | 18.2507 |
| 2000's | 15 (45.45) | 29.6817 |
| 2010's | 11 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grgov, S | 1 |
| Tasić, T | 1 |
| Radovanović-Dinić, B | 1 |
| Benedeto-Stojanov, D | 1 |
| Dewan, K | 1 |
| Lieu, J | 1 |
| Shiratori, Y | 1 |
| Fukuda, K | 1 |
| Konijeti, GG | 1 |
| Deshpande, V | 1 |
| Bunker, CJ | 1 |
| Kato, M | 1 |
| Kawai, T | 1 |
| Takahashi, S | 1 |
| Suzuki, H | 1 |
| Sasaki, H | 1 |
| Nagahara, A | 1 |
| Asaoka, D | 1 |
| Matsuhisa, T | 1 |
| Masaoaka, T | 1 |
| Nishizawa, T | 1 |
| Suzuki, M | 1 |
| Ito, M | 1 |
| Kurihara, N | 1 |
| Omata, F | 1 |
| Mizuno, S | 1 |
| Torii, A | 1 |
| Kawakami, K | 1 |
| Ohkusa, T | 1 |
| Tokunaga, K | 1 |
| Mine, T | 1 |
| Sakaki, N | 1 |
| Mel-Hennawi, D | 1 |
| Ahmed, MR | 1 |
| Peura, DA | 1 |
| Haber, MM | 1 |
| Hunt, B | 1 |
| Atkinson, S | 1 |
| Sasatomi, Y | 1 |
| Takahata, M | 1 |
| Abe, Y | 1 |
| Ishimura, A | 1 |
| Miyake, K | 1 |
| Ogahara, S | 1 |
| Murata, T | 1 |
| Nakashima, H | 1 |
| Maeda, K | 1 |
| Saito, T | 1 |
| Vaezi, MF | 2 |
| Slaughter, JC | 2 |
| Smith, BS | 1 |
| Washington, MK | 1 |
| Jerome, WG | 1 |
| Garrett, CG | 1 |
| Hagaman, D | 1 |
| Goutte, M | 2 |
| Hagaman, DD | 1 |
| Tanner, SB | 1 |
| Duncavage, JA | 1 |
| Allocco, CT | 1 |
| Sparkman, C | 1 |
| Clement, LE | 1 |
| Wasden, CM | 1 |
| Wirth, D | 1 |
| McCafferty, BA | 1 |
| Lanza, DC | 1 |
| Sugiyama, T | 1 |
| Tsuchida, M | 1 |
| Yokota, K | 1 |
| Shimodan, M | 1 |
| Asaka, M | 1 |
| Poe, RH | 1 |
| Kallay, MC | 1 |
| Sato, R | 1 |
| Murakami, K | 1 |
| Watanabe, K | 1 |
| Okimoto, T | 1 |
| Miyajima, H | 1 |
| Ogata, M | 1 |
| Ohtsuka, E | 1 |
| Kodama, M | 1 |
| Saburi, Y | 1 |
| Fujioka, T | 1 |
| Nasu, M | 1 |
| Sawabata, N | 1 |
| Maeda, H | 1 |
| Takeda, S | 1 |
| Inoue, M | 1 |
| Koma, M | 1 |
| Tokunaga, T | 1 |
| Matsuda, H | 1 |
| Marusic, M | 1 |
| Babic, Z | 1 |
| Nesanovic, M | 1 |
| Lucijanic-Mlinac, M | 1 |
| Stajcar, V | 1 |
| Yüksel, H | 1 |
| Yilmaz, O | 1 |
| Kirmaz, C | 1 |
| Aydoğdu, S | 1 |
| Kasirga, E | 1 |
| Kim, SS | 1 |
| Meitner, P | 1 |
| Konkin, TA | 1 |
| Cho, YS | 1 |
| Resnick, MB | 1 |
| Moss, SF | 1 |
| Baldi, F | 1 |
| Cappiello, R | 1 |
| Cavoli, C | 1 |
| Ghersi, S | 1 |
| Torresan, F | 1 |
| Roda, E | 1 |
| Hilmer, SN | 1 |
| Heap, TR | 1 |
| Eckstein, RP | 1 |
| Lauer, CS | 1 |
| Shenfield, GM | 1 |
| García de Hombre, AM | 1 |
| Watari, J | 1 |
| Das, KK | 1 |
| Amenta, PS | 1 |
| Tanabe, H | 1 |
| Tanaka, A | 1 |
| Geng, X | 1 |
| Lin, JJ | 1 |
| Kohgo, Y | 1 |
| Das, KM | 1 |
| Lamouliatte, H | 1 |
| Nakao, K | 1 |
| Imoto, I | 1 |
| Ikemura, N | 1 |
| Shibata, T | 1 |
| Takaji, S | 1 |
| Taguchi, Y | 1 |
| Misaki, M | 1 |
| Yamauchi, K | 1 |
| Yamazaki, N | 1 |
| Viljakka, M | 1 |
| Nevalainen, J | 1 |
| Isolauri, J | 1 |
| Dattilo, M | 1 |
| Figura, N | 1 |
| Zhang, T | 1 |
| O'Keefe, SJ | 1 |
| Winter, T | 1 |
| Marks, IN | 1 |
| Ogden, J | 1 |
| Schnyder, B | 1 |
| Helbling, A | 1 |
| Pichler, WJ | 1 |
| Dave, B | 1 |
| Rubin, W | 1 |
| El-Serag, HB | 1 |
| Lee, P | 1 |
| Buchner, A | 1 |
| Inadomi, JM | 1 |
| Gavin, M | 1 |
| McCarthy, DM | 1 |
| Grigor'ev, PIa | 1 |
| Iakovenko, EP | 1 |
| Talanova, EV | 1 |
| Malfertheiner, P | 1 |
| Sakurane, M | 1 |
| Shiotani, A | 1 |
| Furukawa, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Application of Vagus Nerve Preservation in Minimally Invasive Surgery for Early Lung Cancer[NCT04125979] | 120 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | |||
| Prospective Randomized Controlled Study on the Effects of Vagus Nerve Pulmonary Branch Preservation During Video-assisted Thoracic Surgery Lobectomy in Non-small Cell Lung Cancer: Can it Decrease Postoperative Cough and Pulmonary Complications[NCT04923412] | 214 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| Assessing the Impacts of an Upper Esophageal Sphincter Assist Device on Laryngeal Symptoms and Salivary Pepsin: A Pilot Study[NCT02552966] | 20 participants (Actual) | Interventional | 2015-09-01 | Completed | |||
| Post-nasal Drainage as an Extraesophageal Manifestation of Reflux[NCT00199953] | Phase 2 | 50 participants | Interventional | 2002-06-30 | Completed | ||
| A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis[NCT00369265] | Phase 4 | 18 participants (Actual) | Interventional | 2006-08-31 | Terminated (stopped due to Pharmaceutical company purchased by another company and funding was terminated.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
GERDQ score. Scale of 0-12, higher score indicates increased symptom severity. (NCT02552966)
Timeframe: 2 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| UESAD | 8.6 |
NGSSI questionnaire score (NCT02552966)
Timeframe: 2 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| UESAD | 26.8 |
Respiratory symptom index (RSI) score. Values between 0 and 45. Higher value is associated with increased symptom severity. (NCT02552966)
Timeframe: 2 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| UESAD | 19.4 |
Average salivary pepsin concentration (NCT02552966)
Timeframe: 2 weeks
| Intervention | ng/mL (Mean) |
|---|---|
| UESAD | 158.4 |
3 reviews available for lansoprazole and Chronic Disease
| Article | Year |
|---|---|
[Expanded indication of National Health Insurance for H. pylori associated gastritis].
Topics: Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Gast | 2014 |
Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Chemotherapy, Adj | 1995 |
Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1998 |
14 trials available for lansoprazole and Chronic Disease
| Article | Year |
|---|---|
Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Biopsy; Chronic Disease; Clarith | 2016 |
A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion.
Topics: Acoustic Impedance Tests; Administration, Oral; Audiometry; Audiometry, Pure-Tone; Child; Child, Pre | 2018 |
Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Case-Control Studies; Child; Child, Prescho | 2015 |
Dilated intercellular space in chronic laryngitis and gastro-oesophageal reflux disease: at baseline and post-lansoprazole therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Biopsy; Chronic Disease; Dila | 2010 |
Proton pump inhibitor therapy improves symptoms in postnasal drainage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Chronic Disease; Education, Medical, Continuing; Enz | 2010 |
Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Chronic Disease; | 2004 |
Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2005 |
Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Cough; Enz | 2006 |
Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Distribution; Aged; Chronic Disease; Cost of Ill | 1997 |
Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer; | 1998 |
Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Chronic Disease; Cros | 1999 |
Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Chronic Disease; Colonic Disea | 1999 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Therapeutic effects of antibacterial treatment for intractable skin diseases in Helicobacter pylori-positive Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2002 |
16 other studies available for lansoprazole and Chronic Disease
| Article | Year |
|---|---|
Collagenous colitis diagnosed by endoscopically induced mucosal tears.
Topics: Aged; Chronic Disease; Colitis, Collagenous; Colon; Diarrhea; Endoscopy, Digestive System; Humans; I | 2019 |
An unusual case of chronic diarrhea. Lansoprazole-induced microscopic colitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged, 80 and over; Biopsy, Needle; Chronic Disease; Colitis | 2013 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter I | 2014 |
Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2010 |
[Case of suspicious lansoprazole-associated collagenous colitis in ANCA-associated nephritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Antibodies, Antineutrophil Cytopla | 2010 |
Improvement of long-standing iron-deficiency anemia in adults after eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial | 2002 |
Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Chronic Disease; Cisapride; | 2003 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Asthmatic Agents; Anti-Ulcer Agents; Asthma; Child; Ch | 2006 |
Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after H. pylori eradication in chronic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2006 |
Microscopic colitis associated with exposure to lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Biopsy; Chronic Disease; Colitis, Collagenous; Coliti | 2006 |
[Otorhinolaringologyc approach of the chronic cough. Clinical case].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antitussive Agents; Chronic Disease; Cou | 2007 |
Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective | 2008 |
Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarke | 1997 |
[The effectiveness of 7-day combined Helicobacter eradication therapy in patients with peptic ulcer and chronic gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chronic Disease | 2001 |
Helicobacter pylori eradication in functional dyspepsia: new evidence for symptomatic benefit.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chronic Disease; Dyspepsia; Gastritis; Helicobacter Infecti | 2001 |